Targeting mesenchymal stem cell therapy for severe pneumonia patients

doi:10.4252/wjsc.v13.i2.139

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7769)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

460

WORD

202

HTML

3913

Figures (1-1)

376

Tables (1-1)

256

Sum=5207

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

309

Download

700

Sum=1009

Publishing Process of This Article

Item

Count

Browse

499

Download

1054

Sum=1553

Feb 26, 2021 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Feb 26, 2021; 13(2): 139-154
Published online Feb 26, 2021. doi: 10.4252/wjsc.v13.i2.139

Open in New Tab Full Size Figure Download Figure

Figure 1 Five major perks of mesenchymal stem cells therapies for pneumonia. NO: Nitric oxide; COX2: Cyclooxygenase 2; TGF: Transforming growth factor; IL: Interleukin; EVs: Extracellular vesicles; PGE-2: Prostaglandin E2; SDF-1: Stromal cell-derived factor-1; VCAM-1: Vascular cell adhesion molecule-1; VLA-4: Very late antigen-4; MSCs: Mesenchymal stem cells; CXCR4: CXC chemokine receptor 4.

Citation: Lam G, Zhou Y, Wang JX, Tsui YP. Targeting mesenchymal stem cell therapy for severe pneumonia patients. World J Stem Cells 2021; 13(2): 139-154
URL: https://www.wjgnet.com/1948-0210/full/v13/i2/139.htm
DOI: https://dx.doi.org/10.4252/wjsc.v13.i2.139